Compare Keel Infrastructure Corp. Common Stock (KEEL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keel Infrastructure Corp. Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Keel Infrastructure Corp. Common Stock trades at $3.08 (market cap $1.93B), while Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 39.5× Keel Infrastructure Corp. Common Stock's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Keel Infrastructure Corp. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keel Infrastructure Corp. Common Stock for 1 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| KEEL | REGN | |
|---|---|---|
Market Cap | $1.93B | $76.14B |
Volume | 30,868,523 | 500,239 |
Sector | Technology | Health |
52-Week High | $6.66 | $852.03 |
52-Week Low | $1.71 | $557.73 |
Typical Hold Time | 1 Days | 107 Days |
Enterprise Value | $2.25B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keel Infrastructure Corp. Common Stock
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
